[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"painless-gastrointestinal-endoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:painless-gastrointestinal-endoscopy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100613800","a-clinical-study-to-evaluate-the-efficacy-and-safety-of-hyoscine-butylbromide-capsules-for-preoperative-preparation-in-painless-gastrointestinal-endoscopy-procedures-100613800",false,"NCT07271303","A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures","A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years, regardless of sex;\n* Patients scheduled to undergo painless gastrointestinal endoscopy examination or endoscopic surgery, which must include upper gastrointestinal endoscopy;\n* Voluntary participation based on the free will of the subject or their legal guardian, with signed informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of upper gastrointestinal surgery or colorectal surgery;\n* American Society of Anesthesiologists (ASA) classification ≥ Grade III;\n* Patients with severe cardiac conditions, including severe arrhythmia, structural heart disease, or other serious cardiac disorders;\n* Significant hepatic or renal dysfunction affecting drug metabolism, defined as ALT \\> 2.5 × ULN, AST \\> 2.5 × ULN, or Scr \\> 1.5 × ULN;\n* Organic pyloric stenosis, paralytic ileus, or other severe organic gastrointestinal diseases that are unsuitable for painless gastrointestinal endoscopy;\n* Patients with suspected gastrointestinal ulcer bleeding or perforation;\n* Patients with glaucoma or prostatic hypertrophy;\n* Pregnant or lactating women;\n* Known hypersensitivity to any component of the study drug;\n* Use of medications affecting gastrointestinal motility within 7 days prior to study enrollment;\n* Other conditions unsuitable for painless endoscopy procedures;\n* Participation in another drug or medical device clinical trial within 30 days prior to study enrollment;\n* Patients deemed unsuitable for participation in this clinical study by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"NA","Gastrointestinal endoscopy procedures, including upper gastrointestinal endoscopy and colorectal endoscopy, represent a fundamental and important method for examining and managing digestive tract diseases, with both diagnostic and therapeutic applications. They are also utilized as effective tools for surveillance of gastrointestinal tumors. During upper gastrointestinal endoscopy procedures, gastric peristalsis may restrict the operative field of view and access, significantly affecting procedural precision. Excessive peristalsis not only affects the observation of simple lesions but also impacts other procedural maneuvers Therefore, during upper gastrointestinal endoscopy procedures, antispasmodic agents are commonly used to suppress gastrointestinal motility, ultimately facilitating endoscopic visualization. However, most antispasmodic agents, such as hyoscine butylbromide (Buscopan), cimetropium bromide (Algiron), and atropine, must be administered by injection. Intravenous or intramuscular administration causes patient pain and anxiety, and increases medical costs. Some researchers have taken an alternative approach by spraying L-menthol onto the gastric mucosa during gastroscopy to reduce gastric peristalsis. Although study results and adverse reaction profiles have demonstrated its superiority, the application process still presents operational inconveniences. Furthermore, these drugs should be used with caution as they may cause potential adverse reactions, including dry mouth, urinary retention, temporary impairment of visual accommodation, palpitations, anaphylactic shock, and hyperglycemia.",[27],"Painless Gastrointestinal Endoscopy",[29,30,31],"Painless gastrointestinal endoscopy","Hyoscine Butylbromide","Preoperative Preparation","NOT_YET_RECRUITING","2026-01-15",{"date":35,"type":36},"2026-01-20","ACTUAL",{"date":38,"type":21},"2026-02-01",{"date":40,"type":21},"2026-12-01",{"name":42,"class":43},"Shanghai Jiao Tong University School of Medicine","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100562514","anesthesia-induction-scheme-for-painless-gastrointestinal-endoscopy-patients-based-on-nociceptive-stimulation-monitoring-100562514","NCT06604156","Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring","The Effect of the Nociception Index (qNOX) in Painless Gastrointestinal Endoscopy :a Clinical Study","Inclusion Criteria:\n\n1. Aged 18-60 years old;\n2. American Society of Anesthesiologists (ASA) Class I-III;\n3. Body mass index (BMI): 18-30 kg\u002Fm\\^2;\n4. Individuals scheduled for elective gastroscopy and colonoscopy examinations;\n5. Willing to comply with the experimental procedures and voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Individuals with allergies to sedatives\u002Fanesthetic drugs or other severe anesthetic risks;\n3. Patients with chronic preoperative pain or a history of substance abuse;\n4. Individuals with severe neurological diseases, such as stroke, hemiplegia, seizures, epilepsy, etc.;\n5. Patients with clearly difficult airways, such as those with limited mouth opening, neck or jaw mobility restrictions, rheumatoid arthritis, or temporomandibular joint disorders;\n6. Individuals with respiratory diseases, such as bronchitis, asthma, chronic obstructive pulmonary disease, or acute respiratory infections, which may lead to increased airway sensitivity;\n7. Patients with chronic pharyngitis, laryngitis, laryngeal edema, or recurrent laryngeal nerve paralysis that may affect normal throat function;\n8. Individuals with esophagitis, esophageal strictures, or esophageal motility disorders that may cause difficulty swallowing or reflux;\n9. Patients with poorly controlled life-threatening cardiovascular diseases, such as uncontrolled severe hypertension, severe arrhythmias, or unstable angina; 10.10.Patients with liver dysfunction (Child-Pugh grade C or above), acute upper gastrointestinal bleeding with shock, severe anemia, or gastrointestinal obstruction with retained gastric contents.","60 Years",{"count":53,"type":21},220,"OBSERVATIONAL","Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. However, in the context of sedation for gastrointestinal endoscopy, how the dynamic changes of the quantitative consciousness index (qCON) and the quantitative nociception index (qNOX) reflect the depth of sedation and nociceptive response remains unclear. Safe and effective sedation monitoring includes both direct visual monitoring and physiological monitoring, that is, monitoring the patient's hemodynamics and depth of sedation. This study utilizes qCON and qNOX monitoring to assess the sedation and analgesic states of patients undergoing painless gastroenterological endoscopy. By combining visual assessment (cough reflex, respiratory depression, and limb movement) with clinical physiological monitoring (vital signs monitoring and pulse oximetry), the aim is to explore the optimal sedation range for gastrointestinal endoscopy under sedation, providing new anesthesia monitoring tools for clinical use.",[57,58,27],"Depth of Anesthesia","Nociception",[60,61,62],"Painless Gastrointestinal endoscopy","depth of anesthesia","nociception","RECRUITING","2025-03-04",{"date":66,"type":36},"2025-03-06",{"date":68,"type":36},"2024-09-01",{"date":70,"type":21},"2025-10-31",{"name":72,"class":43},"Min Su",1]